Night Sweats in Women: What Could Be Causing It and What to Do

What Exactly Counts as Night Sweats?

Night sweats are episodes of excessive sweating during sleep that soak your clothing or bedding and are not explained by a hot room or too many blankets. Feeling warm and kicking off the covers does not qualify. True night sweats are drenching. They can wake you repeatedly, drop your core temperature sharply enough to cause chills, and leave sheets visibly wet.

The medical term is "sleep hyperhidrosis" when there is no obvious cause, and "secondary hyperhidrosis" when a specific driver is found. Most clinical guidelines distinguish between physiologic sweating tied to ambient temperature and pathologic sweating tied to internal thermoregulatory dysfunction, a distinction that matters because the two have entirely different workups.

For women specifically, the experience is layered. Hormonal fluctuations create a thermoregulatory set-point problem that men rarely face at equivalent intensity. The hypothalamic zone that triggers sweating narrows during estrogen decline, meaning your body fires a sweat response at smaller temperature provocations than it did before. That narrowed thermoneutral zone is the core physiologic mechanism behind menopausal vasomotor symptoms.

The Full Differential: Every Common Cause Organized by Life Stage

No single cause explains night sweats across all women. Your age, hormonal status, medication list, and immune health all shift which diagnosis sits at the top of the list.

Reproductive Years (Ages 18-40)

Night sweats during your menstrual cycle are more common than most clinicians acknowledge. Progesterone is thermogenic, meaning it raises your baseline body temperature. Progesterone raises basal body temperature by approximately 0.3-0.5°C after ovulation, which can produce sweating in the luteal phase. Women with PCOS who have erratic cycles and unpredictable progesterone surges may notice this more intensely.

Anxiety and panic disorder also produce nocturnal sweating through adrenergic activation. Night sweats are a recognized somatic symptom of generalized anxiety disorder, and the link is stronger in women, who are diagnosed with anxiety disorders at roughly twice the rate of men.

Hyperthyroidism accelerates metabolic rate and heat production at every life stage. Graves disease, the most common cause of hyperthyroidism, affects women four to eight times more often than men and is a well-recognized cause of night sweats, palpitations, and heat intolerance.

Trying to Conceive and Early Pregnancy

If you are in the two-week wait and waking drenched, elevated progesterone after ovulation is the likely culprit. Fever-associated night sweats in early pregnancy warrant immediate attention because fever above 38°C in the first trimester carries teratogenic risk. ACOG advises prompt evaluation and treatment of fever in pregnant women, though the guidance specific to fever as a teratogen is discussed in their immunization and infectious disease materials.

Postpartum and Lactation

Postpartum night sweats are nearly universal and genuinely normal. After delivery, estrogen and progesterone drop sharply and the body uses sweating to shed the extra fluid volume accumulated during pregnancy. Postpartum diaphoresis typically peaks in the first week after delivery and resolves within two to six weeks. If sweats persist beyond six weeks or come with fever, wound signs, or breast redness, infection must be ruled out.

Lactation-associated night sweats deserve their own note. Breastfeeding suppresses estrogen through prolactin-mediated GnRH inhibition. The result is a hypoestrogenic state that mimics perimenopause and can cause sweating, vaginal dryness, and mood shifts throughout the entire nursing period.

Perimenopause (Typically Ages 40-51)

This is the life stage where night sweats are most prevalent and most frequently underdiagnosed, often before periods become irregular. Up to 80% of women report vasomotor symptoms during the menopausal transition, and night sweats are among the earliest and most new. The Study of Women's Health Across the Nation (SWAN) found that vasomotor symptoms can begin three to six years before the final menstrual period, with a median total duration of 7.4 years.

Estrogen fluctuates wildly in perimenopause rather than falling smoothly. That volatility, not just low estrogen, is what drives the thermoregulatory instability. Women who smoke, have higher BMI, experience more psychological stress, or are of Black or Hispanic ethnicity have documented longer and more severe vasomotor symptom duration in the SWAN data.

Post-Menopause

Vasomotor symptoms often, but not always, improve after menopause is established. Women who reach menopause early (before age 45), whether naturally or surgically, tend to have more severe and persistent symptoms. If you are post-menopausal and night sweats start after years of being asymptomatic, that is a pattern worth investigating beyond menopause because new-onset sweats after a symptom-free window raise the question of secondary causes.

Non-Hormonal Medical Causes You Should Not Miss

Infections

Tuberculosis is the textbook night-sweat infection, and the association holds up clinically. Night sweats in TB arise from cytokine-mediated temperature dysregulation. HIV infection, bacterial endocarditis, and disseminated fungal infections such as histoplasmosis are all well-established infectious causes. If you have traveled internationally, have an immunocompromised state, or use intravenous drugs, infections belong high on your differential.

Lymphoma and Malignancy

"Drenching night sweats" are one of the three classic B symptoms of lymphoma, alongside unexplained fever and weight loss of more than 10% body weight in six months. Hodgkin lymphoma has a bimodal age distribution with a peak in the mid-20s, meaning it is not only a middle-age concern. If night sweats are drenching rather than just bothersome, and you have swollen lymph nodes or unexplained weight loss, you need a complete blood count and likely imaging before attributing symptoms to hormones.

Thyroid Disorders

Both hyperthyroidism and the hyperthyroid phase of postpartum thyroiditis cause night sweats. Postpartum thyroiditis affects approximately 5-10% of women in the first year after delivery and can produce a transient hyperthyroid phase that is easily missed.

Medications

Several commonly prescribed drugs cause night sweats as a side effect. Antidepressants (especially SSRIs and SNRIs) are among the most frequent culprits. Paroxetine, venlafaxine, and fluoxetine all list hyperhidrosis as a recognized adverse effect. Tamoxifen, used in breast cancer treatment and chemoprevention, causes vasomotor symptoms in a significant proportion of users. Aromatase inhibitors produce a more severe menopausal state than tamoxifen. GnRH agonists like leuprolide cause medical menopause with intense sweating. If you recently started or changed any of these drugs, medication-induced night sweats are the most likely explanation.

Blood Sugar Dysregulation

Nocturnal hypoglycemia triggers an adrenergic response that produces sweating, shakiness, and waking. Women with type 1 or type 2 diabetes on insulin or sulfonylureas are at risk. Even reactive hypoglycemia in women with insulin resistance or PCOS can produce nocturnal adrenergic surges. PCOS affects approximately 10-15% of women of reproductive age and is associated with insulin resistance, making this an underappreciated connection.

Obstructive Sleep Apnea

OSA is underdiagnosed in women partly because women present atypically, with insomnia, fatigue, and mood symptoms more often than the classic loud snoring. Night sweats occur in OSA through sympathetic nervous system activation during apneic episodes. Women with OSA are more likely than men to report night sweats as a primary complaint, which makes it a particularly relevant differential in this population.

How Night Sweats Are Diagnosed

Your clinician will take a structured history before ordering anything. Expect questions about timing (which part of the night, how often), severity (damp versus soaking), associated symptoms (fever, weight loss, palpitations, mood changes), menstrual history, medication list, and relevant travel or exposures.

The Core Lab Panel

A reasonable first-pass workup for unexplained night sweats in most women includes:

• TSH (to screen for thyroid dysfunction)
• FSH and estradiol (to assess menopausal status, particularly in the 40s)
• Complete blood count with differential (to screen for infection and lymphoma)
• Fasting glucose or HbA1c (to assess glycemic status)
• HIV test (standard of care as a once-in-lifetime screen)
• Comprehensive metabolic panel

The Menopause Society (formerly NAMS) does not require lab confirmation of menopause before treating vasomotor symptoms in women over 45 with typical symptoms. Labs become more important when the clinical picture is atypical, the woman is under 40, or red-flag features are present.

When Imaging Is Needed

Chest X-ray is indicated if tuberculosis or lymphoma is on the differential. CT chest/abdomen/pelvis or PET scan may be ordered if lymphoma remains a concern after initial labs. Pelvic ultrasound is not part of the night-sweat workup unless other pelvic symptoms are present.

Treatment by Cause: What the Evidence Actually Supports

Hormone Therapy for Vasomotor Symptoms

For women with perimenopausal or postmenopausal night sweats, estrogen-based hormone therapy (HT) is the most effective treatment available. The 2022 Menopause Society position statement rates hormone therapy as the most effective treatment for vasomotor symptoms, with a reduction in frequency of 75% or more in most trials. Estrogen is FDA-approved for this indication. Women with a uterus require progestogen co-administration to protect the endometrium.

The Women's Health Initiative (WHI) generated significant fear about hormone therapy, but the nuance matters enormously for women reading this. Reanalysis of WHI data and subsequent trials show that women who begin HT within 10 years of menopause or before age 60 have a favorable benefit-risk profile for most outcomes. That is the timing hypothesis, and it should be part of any informed shared-decision conversation.

Non-Hormonal Prescription Options

For women who cannot or choose not to use hormone therapy (those with hormone-receptor-positive breast cancer history, active clot history, or personal preference), the options have expanded meaningfully.

Fezolinetant (Veozah), a neurokinin B receptor antagonist, received FDA approval in May 2023. It works on the KNDy neurons in the hypothalamus that regulate the thermoregulatory set point. The SKYLIGHT 1 and SKYLIGHT 2 trials showed fezolinetant 45 mg daily reduced moderate-to-severe vasomotor symptom frequency by approximately 60% versus placebo at 12 weeks. It is not a hormone and has no known effect on estrogen levels.

Low-dose paroxetine 7.5 mg (Brisdelle) is the only SSRI with an FDA approval specifically for vasomotor symptoms. The FDA labeling notes it is contraindicated in women taking tamoxifen because paroxetine is a potent CYP2D6 inhibitor that reduces tamoxifen's conversion to its active metabolite endoxifen.

Venlafaxine, gabapentin, and oxybutynin also have supportive evidence from randomized trials, though none carry specific FDA approval for vasomotor symptoms. The MsFLASH network trials systematically compared these agents and found venlafaxine 75 mg comparable to low-dose estrogen in reducing hot flash frequency.

Treating the Underlying Cause

For medication-induced sweating, switching agents or adjusting timing often helps. For thyroid-driven sweats, treating the thyroid disorder resolves symptoms. For OSA, CPAP therapy is first-line. For lymphoma, oncology directs treatment. For postpartum sweats with no red flags, reassurance and moisture-wicking sleepwear are entirely appropriate.

Lifestyle and Behavioral Approaches

Lowering bedroom temperature to 65-68°F, using moisture-wicking bedding, avoiding alcohol within three hours of sleep, and reducing caffeine intake all reduce night-sweat frequency modestly. Cognitive behavioral therapy for menopause-related symptoms reduced hot flash problem rating by 50% in the MenopauseMINDS trial. Hypnotherapy showed a 74% reduction in hot flash score in a randomized trial by Elkins et al., though that study was small. These approaches matter most when pharmacologic options are limited.

Pregnancy and Lactation Considerations

Night sweats during pregnancy are common and usually benign, driven by elevated progesterone and increased metabolic demand. They do not require treatment beyond comfort measures.

Hormone therapy is contraindicated in pregnancy. Women should use reliable contraception if hormone therapy is prescribed during perimenopause, as pregnancy remains possible until 12 months after the final menstrual period.

Fezolinetant is contraindicated in pregnancy. Animal reproductive toxicity data flagged concerns; there are no human pregnancy data. The FDA label for fezolinetant states women of reproductive potential should use effective contraception during treatment.

SSRIs including paroxetine: Paroxetine carries a known association with cardiac septal defects when used in the first trimester and is classified as Pregnancy Category D. ACOG advises weighing the psychiatric risks of discontinuation against fetal risk on a case-by-case basis, but paroxetine should generally be avoided in women actively trying to conceive.

Lactation: SSRIs transfer into breast milk; sertraline has the lowest relative infant dose among them and is generally preferred over paroxetine during breastfeeding. Fezolinetant lactation data are absent. For postpartum women with significant vasomotor symptoms while nursing, a discussion of risks and alternatives with a knowledgeable clinician is warranted.

Who These Treatments Are Right For (and Who Should Look Elsewhere)

The following framework is used by the WomanRx clinical team to match night-sweat treatment to life stage and clinical profile:

| Life Stage / Profile | First Consider | Avoid or Use Caution | |---|---|---| | Perimenopause, no contraindications | Hormone therapy | Paroxetine if on tamoxifen | | Post-menopause, HR+ breast cancer history | Fezolinetant or venlafaxine | Estrogen-containing HT | | Postpartum, breastfeeding | Comfort measures; sertraline if mood comorbidity | Paroxetine, fezolinetant | | Reproductive years, anxiety-driven | CBT, SSRI (not paroxetine if TTC) | HT (not indicated) | | Any stage, OSA suspected | Sleep study first | Treating sweats without addressing OSA | | Any stage, fever + weight loss + sweats | Urgent workup (CBC, imaging) | Empiric hormonal treatment before excluding lymphoma |

Women with PCOS and night sweats from insulin dysregulation may benefit from metformin or lifestyle interventions targeting insulin resistance alongside symptom-specific treatment.

Women with surgical menopause, whether from oophorectomy for endometriosis, cancer prophylaxis, or other reasons, typically experience more severe vasomotor symptoms than women in natural menopause and often need higher estrogen doses to achieve symptom control. ACOG Practice Bulletin 141 addresses management after risk-reducing salpingo-oophorectomy and recommends hormone therapy consideration for symptom management in women without hormone-sensitive cancers.

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in clinical trials, and night-sweat research is not exempt. Most vasomotor symptom trial data come from predominantly white, post-menopausal populations. The SWAN cohort is a notable exception, having enrolled Black, Hispanic, Chinese, and Japanese women alongside white women, and it found meaningful racial and ethnic differences in symptom duration and severity.

Data in perimenopausal women (as opposed to post-menopausal) are thinner. The timing of hormone therapy initiation, optimal duration of fezolinetant, and efficacy of non-hormonal options specifically during perimenopause are areas where extrapolation from post-menopausal data is common but not always validated. This is a genuine limitation of the current evidence base, and your clinician should acknowledge it when discussing your options.

When to Seek Urgent Evaluation

Most night sweats in women have benign, treatable causes. Seek prompt evaluation if you have:

• Soaking sweats paired with unintentional weight loss of more than 5% body weight in six months
• Recurring fevers above 38°C (100.4°F)
• Swollen, painless lymph nodes in the neck, armpit, or groin
• Night sweats that began abruptly after years without them, especially post-menopause
• Any new night sweats in an immunocompromised patient

These combinations warrant same-week evaluation, not watchful waiting.